Turn Therapeutics director granted 21,882 RSUs

Turn Therapeutics Inc. director Martin William Dewhurst received an award of 21,882 restricted stock units (RSUs) of common stock on January 7, 2026 at a price of $0 per unit.

Rhea-AI Filing Summary

Turn Therapeutics Inc. director Martin William Dewhurst received an award of 21,882 restricted stock units (RSUs) of common stock on January 7, 2026 at a price of $0 per unit. Each RSU represents the right to receive one share of common stock.

The 21,882 RSUs vest in full on January 7, 2027, provided Dewhurst continues to serve the company through that date. The award was made under Turn Therapeutics’ 2025 Omnibus Incentive Plan and is held directly by the reporting person.

Insider Trade Summary

Grant/Award: 21,882 shares

Grant/Award 1 txn

Insider Dewhurst Martin William

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,882	$0.00	$0.00

Holdings After Transaction: Common Stock — 21,882 shares (Direct)

Footnotes (1)

1. F1. The securities reported in Column 5 of Table I are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, subject to the applicable vesting schedule and conditions of the applicable RSU award and the Issuer's 2025 Omnibus Incentive Plan. The 21,882 RSUs included in Column 5 of Table I vest in full on January 7, 2027, subject to the reporting person's continuous service to the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Turn Therapeutics (TTRX) report in this Form 4?

Turn Therapeutics reported that director Martin William Dewhurst received 21,882 restricted stock units of common stock on January 7, 2026. These RSUs were granted at a price of $0 per unit as an equity-based compensation award under the company’s 2025 Omnibus Incentive Plan.

How many Turn Therapeutics (TTRX) shares are covered by the new RSU grant?

The grant covers 21,882 restricted stock units, each representing one share of Turn Therapeutics common stock. After this award, the Form 4 shows Dewhurst beneficially owning 21,882 common shares in the form of RSUs, all held in direct ownership.

When do Martin William Dewhurst’s Turn Therapeutics (TTRX) RSUs vest?

All 21,882 restricted stock units vest in full on January 7, 2027. Vesting is conditioned on Dewhurst’s continuous service with Turn Therapeutics through that date, consistent with the vesting schedule and conditions in the applicable RSU award agreement.

What is the exercise or purchase price of the Turn Therapeutics (TTRX) RSUs?

The Form 4 lists a transaction price of $0 per RSU for the 21,882 restricted stock units granted. This reflects that RSUs are typically granted as compensation, giving the holder the right to receive shares without paying a purchase price at vesting.

Under which plan were the Turn Therapeutics (TTRX) RSUs granted to the director?

The restricted stock units were granted under Turn Therapeutics’ 2025 Omnibus Incentive Plan. The plan governs the vesting schedule and conditions, including the requirement that Dewhurst maintain continuous service to receive the 21,882 common shares upon vesting.

Is the Turn Therapeutics (TTRX) RSU award held directly or indirectly by the reporting person?

The Form 4 indicates that the 21,882 restricted stock units are held directly by Martin William Dewhurst. The ownership form is marked as “D” for direct, and no nature of indirect beneficial ownership is disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:31 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dewhurst Martin William

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CA 91362

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		21,882	A	$0	21,882(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities reported in Column 5 of Table I are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, subject to the applicable vesting schedule and conditions of the applicable RSU award and the Issuer's 2025 Omnibus Incentive Plan. The 21,882 RSUs included in Column 5 of Table I vest in full on January 7, 2027, subject to the reporting person's continuous service to the Issuer.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Martin William Dewhurst	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.